BEAVERTON, Ore., July 13, 2026 /PRNewswire/ -- Oregon Voices for Biomedical Research (OVBR) – a nonprofit advocacy group of veterinarians, scientists, healthcare professionals and concerned Oregonians – today released the results of an independent poll demonstrating the majority of Americans support animal-based research to allow for continued human and animal health advancements. The survey was conducted by Ipsos, a global market research and polling company. Continue Reading Oregon Voices for

Mouse study uncovers how oxygen-sensing transcription factors HIF1α and HIF2α regulate different aspects of muscle physiology JEOLLANAM-DO PROVINCE, South Korea, July 13, 2026 /PRNewswire/ -- A new study published in the Journal of Clinical Investigation suggests that skeletal muscle does more than power movement. Using three complementary mouse models, researchers found that two oxygen-sensing proteins, HIF1α and HIF2α, have sharply different roles in skeletal muscle physiology. HIF1α reshape

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular

In this free webinar, learn how normalcy, identity and daily-life disruption influence patient decisions about trial participation and treatment. The featured speaker will share an evidence-based perspective drawn from patient and caregiver narratives across therapeutic areas. Attendees will explore how clinical trial assumptions can miss what is relevant and important to patients, and how these insights can support protocol design, patient communications and more patient-informed clinical devel

— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval — BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the s

In this free webinar, gain insight into robust formulation, process and conjugation chemistries for ligand-conjugated lipid nanoparticles (LNPs). The featured speakers will discuss the assessment of targeted LNP activity in cellular models, focusing on target engagement to inform formulation design iteration. Attendees will also gain insight into functional evaluation of targeted LNPs in preclinical models, linking target expression, biodistribution and immunogenicity. TORONTO, July 13, 2026 /PR

Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated healt

Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts SAN DIEGO, July 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those pr

Slavmed Medical Center has performed Armenia’s first robotic remote surgery carried out by one of the world’s leading urologists, Professor Alexandre Mottrie. Performing Armenia’s first robotic remote surgery is a landmark achievement for us” — Armine Hovakimyan Slavmed founder YEREVAN, ARMENIA, July 13, 2026 / EINPresswire.com / -- Slavmed Medical Center has performed Armenia’s first robotic remote surgery, marking a new milestone in the country’s healthcare sector. The procedure was carried ou

SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B meningococcal (MenB) vaccine candidate developed using the company's proprietary OMV Plus® platform. This milestone marks a significant step in the concurrent global development of DX-104, following the initia